Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA7 | P43166 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | XDH | P47989 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31414452 | 1.00 | KDM4E (0.79) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL11435129 | 0.86 | CA1 (0.61) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL583987 | 0.81 | ALDH1A1 (0.79) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL1620578 | 0.81 | ALDH1A1 (0.79) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL30014968 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL23970743 | 0.80 | KDM4E (0.76) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL29642232 | 0.80 | KDM4E (0.76) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL567975 | 0.80 | ALDH1A1 (0.76) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL31287794 | 0.80 | ALDH1A1 (0.76) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL21326545 | 0.79 | CA12 (0.53) | KDM4EALDH1A1CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444708-B1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250129048-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4444708-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-118369317-A | Melanocortin 4 receptor antagonists and uses thereof | 辉瑞大药厂 | 2024-07-19 | — | — | CN | disclosed |
| CN-109069514-B | Antibacterial compound and application thereof | 结核病药物开发全球联盟公司 | 2023-12-29 | — | — | CN | disclosed |
| WO-2023105387-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023105387-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | PFIZER INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | PFIZER INC. (US) | 2023-06-08 | — | — | US | disclosed |
| CN-116113635-A | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof | 辉瑞公司 | 2023-05-12 | — | — | CN | disclosed |
| WO-2010028981-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063101-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | US | disclosed |
| WO-2009083553-A1 | AZINE COMPOUNDS AS GLUCOKINASE ACTIVATORS | RHEOSCIENCE A/S (DK) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009083553-A1 | AZINE COMPOUNDS AS GLUCOKINASE ACTIVATORS | RHEOSCIENCE A/S (DK) | 2009-07-09 | — | — | WO | disclosed |
| US-6420363-B1 | Mono- or polyenic carboxylic acid derivatives | EISAI CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-6291508-B1 | POTENT ABILITY TO BIND TO RETINOIC ACID RECEPTORS THUS USEFUL IN TREATING PSORIASIS AND RHEUMATOID ARTHRITIS. | EISAI CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| US-6133283-A | Mono- or polyenic carboxylic acid derivatives | EISAI CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| US-6030964-A | BINDS TO RETINOIC ACID RECEPTORS AND USEFUL FOR TREATING PSORIASIS, AUTOIMMUNE DISEASES, TUMORS, RHEUMATOID ARTHRITIS AND FOR INDUCING IMMUNOSUPPRESSION IN ORGAN TRANSPLANTATION | EISAI CO., LTD. (JP) | 2000-02-29 | — | — | US | disclosed |
| US-5977125-A | Mono-or polyenic carboxylic acid derivatives | EISAI CO., LTD. (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0790228-A1 | MONO- OR POLYENIC CARBOXYLIC ACID DERIVATIVE | Eisai Co., Ltd. (JP) | 1997-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063101-A1 | NEW BENZIMIDAZOLE DERIVATIVES | CYP3A7, ECI1, CYP2B6 | KDM4E 1959/4885ALDH1A1 39/4885CA1 4371/4885 |
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | MC4R, MC2R, NPY4R | KDM4E 1189/4885ALDH1A1 3488/4885CA1 3215/4885 |
| US-20250129048-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | MC4R, MC3R, MC2R | KDM4E 1833/4885ALDH1A1 3955/4885CA1 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.